FACTBOX-Nestle CEO Schneider's top deals

Feb 13 (Reuters) - Nestle Chief Executive Mark Schneider has made great strides in positioning the world's largest food company for the future with his aggressive deal-making since taking over in January 2017.

The 54-year-old German-American has set a vision on selling premium products in fast-growing categories such as pet food and coffee while disposing of businesses in slower-growth areas such as chocolate and processed meat.

Schneider promised to replace as much as 10% of Nestle's existing portfolio by the end of 2020 and has conducted more than 50 transactions and reviews since he took the helm. (https://reut.rs/34b1H2z)

In October Schneider indicated he would not stop at the 10% target, describing the portfolio review as an "ongoing process".

Below is a summary of the top deals under Schneider's tenure:


* January - Nestle expands its medical nutrition portfolio with the acquisition of Zenpep from Allergan. Zenpep is a medication for people who have a pancreas that is unable to provide sufficient enzymes to properly digest fats, proteins and sugars.

* February - Nestle's health science arm invests an additional $200 million in Aimmune Therapeutics after the drugmaker won U.S. approval for its peanut allergy therapy. 2019:

* May - Sells its skin health unit, maker of the Cetaphil and Proactiv skincare brands, to private equity firm EQT Partners for 10.2 billion Swiss francs ($10.1 billion). The business accounted for about 3% of group sales.

* December - Agrees a $4 billion sale to Froneri of its U.S. ice-cream business, which includes Haagen-Daazs. Froneri is Nestle's ice-cream joint venture with private equity firm PAI Partners.

* December - Nestle agrees to sell a majority stake in its packaged meat business, Herta, to family-run Spanish company Casa Tarradellas to create a joint venture in which it would hold a 40% stake.


* January - Sells its U.S. confectionary business to Ferrero for $2.8 billion, handing over control of brands Butterfinger, Crunch and Baby Ruth to the Italian manufacturer. The deal marked Schneider's first big sale, underlining the shift in focus towards healthier products. (https://reut.rs/2snYMX2)

* May - Strikes $7.2 billion licensing deal https://uk.reuters.com/article/us-starbucks-m-a-nestle/nestle-and-starbucks-stri k e - 7 - 1 5 - b i l l i o n - c o f f e e - l i c e n s i n g - d e a l - i d U K K B N 1 I 8 0 C G with Starbucks for exclusive rights to sell the U.S. chains packaged coffees and teas around the world, tying a premium brand to Nestles global distribution muscle's. The contract includes Starbucks-branded capsules for Nestle's Nespresso and Dolce Gusto single-serve brewers.

* September - Sells its Gerber Life Insurance business https://www.reuters.com/article/us-nestle-divestiture/nestle-to-sell-gerber-life - i n s u r a n c e - u n i t - f o r - 1 - 5 5 - b i l l i o n - i d U S K C N 1 L X 2 F P to Western and Southern Financial Group for $1.55 billion in cash. The insurer, which sold life cover for families and juveniles, had sales of $856 million in 2017, equating ot less than 1% of group sales that year.


* September - Nestle acquires majority interest in California-based coffee roaster Blue Bottle Coffee https://www.reuters.com/article/us-bluebottle-m-a-nestle/nestle-to-brew-high-end - c o f f e e - w i t h - b l u e - b o t t l e - b u y - i d U S K C N 1 B P 2 D 7 , its first step into the fast-growing, super-premium coffee shop segment.

* September - Agrees to buy California-based Sweet Earth https://www.reuters.com/article/nestle-ma/nestle-to-buy-sweet-earth-vegetarian-f o o d s - i d U S A S B 0 B I F L , the plant-based foods manufacturer behind the Awesome burger, for an undisclosed sum.

* December - Signs a $2.3 billion deal https://www.reuters.com/article/us-nestle-m-a-atrium/nestle-to-buy-vitamin-maker - a t r i u m - i n n o v a t i o n s - f o r - 2 - 3 - b i l l i o n - i d U S K B N 1 D Z 2 E K to buy privately held Atrium Innovations, a Canadian vitamin maker, from a group of investors led by Permira Funds. The cash deal gives Nestle exposure to the consumer healthcare category. (Compiled by Siddharth Cavale and Nivedita Balu in Bengaluru Editing by David Goodman)